Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Protagonist Therapeutics Inc (PTGX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 320,788
  • Shares Outstanding, K 23,347
  • Annual Sales, $ 30,930 K
  • Annual Income, $ -38,920 K
  • 60-Month Beta 2.05
  • Price/Sales 10.04
  • Price/Cash Flow N/A
  • Price/Book 2.86

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.64
  • Number of Estimates 2
  • High Estimate -0.59
  • Low Estimate -0.70
  • Prior Year -0.36
  • Growth Rate Est. (year over year) -77.78%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.72 +77.98%
on 02/28/19
14.00 -1.86%
on 03/22/19
+5.71 (+71.11%)
since 02/22/19
3-Month
6.23 +120.55%
on 12/27/18
14.00 -1.86%
on 03/22/19
+7.07 (+106.00%)
since 12/21/18
52-Week
5.49 +150.27%
on 11/28/18
21.26 -35.37%
on 03/23/18
-5.99 (-30.36%)
since 03/22/18

Most Recent Stories

More News
Protagonist Therapeutics: 4Q Earnings Snapshot

NEWARK, Calif. (AP) _ Protagonist Therapeutics Inc. (PTGX) on Tuesday reported a loss of $13.9 million in its fourth quarter.

PTGX : 13.74 (+3.31%)
Protagonist Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results

Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported its financial results for the fourth quarter and full year ended December 31, 2018, and provided a corporate update on its clinical development...

PTGX : 13.74 (+3.31%)
Protagonist Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results

Protagonist Therapeutics, Inc. (Nasdaq:PTGX) will announce fourth quarter and year end 2018 financial results after the NASDAQ market closes on Tuesday, March 12, 2019. Protagonist management will host...

PTGX : 13.74 (+3.31%)
Protagonist Therapeutics to Present at the Leerink Partners 8th Annual Global Healthcare Conference on Thursday, Feb. 28

Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will provide a corporate overview at the Leerink Partners 8th Annual Global...

PTGX : 13.74 (+3.31%)
Investor Expectations to Drive Momentum within Continental Resources, Protagonist Therapeutics, Mobile Mini, J & J Snack Foods, Griffon, and Nordson -- Discovering Underlying Factors of Influence

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Continental Resources, Inc....

PTGX : 13.74 (+3.31%)
JJSF : 154.63 (-0.87%)
MINI : 33.08 (-4.59%)
NDSN : 127.95 (-4.38%)
GFF : 18.11 (-3.77%)
CLR : 42.38 (-4.18%)
Protagonist Therapeutics Reports Granting of Inducement Award

Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on Jan. 15, 2019, it issued an inducement award to Suneel Gupta, Ph.D., the Company's recently hired Executive Vice President of Clinical...

PTGX : 13.74 (+3.31%)
Protagonist Therapeutics Initiates Phase 2 Trial of Novel Hepcidin Mimetic PTG-300 for the Treatment of Patients with Beta Thalassemia

Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that the first patient has been dosed in the Phase 2 study of PTG-300, an injectable hepcidin mimetic peptide in development for the treatment...

PTGX : 13.74 (+3.31%)
Protagonist Therapeutics Appoints Suneel K. Gupta, Ph.D., as Executive Vice President of Clinical Operations and Pharmacology

Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today announced the appointment of Suneel Gupta, Ph.D., as Executive Vice President of Clinical Operations and Clinical Pharmacology. In this role, Dr. Gupta...

PTGX : 13.74 (+3.31%)
Protagonist Therapeutics Initiates Phase 1 Trial of Oral, Gut-Restricted, Alpha-4-Beta-7 Integrin Antagonist PN-10943

Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced the initiation of dosing in the Phase 1 study of PN-10943, an oral, gut-restricted alpha-4-beta-7 integrin antagonist peptide in development...

PTGX : 13.74 (+3.31%)
Protagonist Therapeutics to Present at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will provide a corporate overview at the BMO Capital Markets 2018 Prescriptions...

PTGX : 13.74 (+3.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is in the Top 1%. Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade PTGX with:

Business Summary

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and...

See More

Key Turning Points

2nd Resistance Point 14.51
1st Resistance Point 14.13
Last Price 13.74
1st Support Level 13.23
2nd Support Level 12.71

See More

52-Week High 21.26
Fibonacci 61.8% 15.24
Last Price 13.74
Fibonacci 50% 13.38
Fibonacci 38.2% 11.51
52-Week Low 5.49

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar